Aptus Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Aptus Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50,381	Closed	-$1.22M	–	1568
2025 Q1	$1.22M	Buy	50,381 +1,674	+3%	+$52.9K	0.01%	472
2024 Q4	$1.96M	Buy	48,707 +10,564	+28%	+$602K	0.02%	400
2024 Q3	$2.41M	Buy	38,143 +9,699	+34%	+$569K	0.04%	294
2024 Q2	$1.51M	Buy	+28,444	New	+$1.86M	0.03%	327

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Aptus Capital Advisors's VKTX Position: Q2 2025 in Review

Aptus Capital Advisors sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 50,381 shares — an estimated $1.22M sold.

Aptus Capital Advisors first reported a position in VKTX in Q2 2024 and held it in 4 quarters. The position peaked at $2.41M in Q3 2024. 392 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

Aptus Capital Advisors reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
Aptus Capital Advisors sold 50,381 Viking Therapeutics shares in Q2 2025, an estimated $1.22M.
Aptus Capital Advisors first reported a position in Viking Therapeutics in Q2 2024 and held it in 4 quarters.
Aptus Capital Advisors's Viking Therapeutics position peaked at $2.41M in Q3 2024.
392 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on Aptus Capital Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.